Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 16/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3474804 | 0.92 | REN (0.34) | REN | |
| SCHEMBL27740232 | 0.85 | REN (0.43) | RENKCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3277339 | 0.82 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL13161136 | 0.82 | REN (0.42) | RENCYP3A4 | |
| SCHEMBL3081978 | 0.81 | REN (0.48) | REN | |
| SCHEMBL13030781 | 0.81 | REN (0.48) | REN | |
| SCHEMBL13030786 | 0.81 | REN (0.52) | REN | |
| SCHEMBL3076669 | 0.81 | REN (0.52) | REN | |
| SCHEMBL3076004 | 0.80 | REN (0.44) | REN | |
| SCHEMBL8284795 | 0.80 | REN (0.44) | REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7799779-B2 | Substituted piperidines as renin inhibitors | NOVARTIS AG (CH) | 2010-09-21 | — | — | US | disclosed |
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306064-A1 | Substituted Piperidines as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885CYP3A4 659/4885KCNH2 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.